Prevent Alzheimer Program

Prevent-AD program

The PREVENT-Alzheimer Program

The PREVENT-Alzheimer program wants to recruit 500 participants. Their contributions will be the key to finding strategies that can slow or reverse brain changes that may occur in older people who do not suffer from dementia. Recruitment is currently closed.

To our knowledge, this program is the first of its kind worldwide. 

To participate in the study or for more information, please dial toll free number: 
1 855-888-4485



PREVENT-Alzheimer means Pre-symptomatic evaluation of experimental or novel treatments for Alzheimer’s Disease. The PREVENT-Alzheimer program is the principal clinical research activity of the Centre for Studies on Prevention of Alzheimer's Disease, or  StoP-AD Centre. The goal of this program is to study memory and brain changes in healthy people over the age of 55. While some people in this age group begin to develop apparent memory problems, many more may have undetected brain changes that mark the very beginning of the disease long before the onset of symptoms.
With rapid advances in technology, such as high-resolution brain scanning methods or the precise examination of brain chemicals, we can now detect early evidence of brain changes. What’s more, we can likely track these changes over time. These brain changes are more likely to occur in individuals who have had either a parent or sibling affected by AD. This is why we require that our participants have a close family member affected by the disease.

Double-blind methods

The program will examine its participants every year for changes in memory, brain chemistry, and scan results. Program participants will be invited to join one of several clinical trials (experiments) run by the StoP-AD Centre to test the effectiveness of prevention strategies. These trials will run typically for two years and will use traditional “double-blind” methods to compare effects of interventions vs. placebo. Double-blind means that neither project staff nor participants themselves will be told who has been assigned to the active agent or placebo groups. A placebo, or a treatment that appears identical to an active agent but is in fact inactive, is used as a control for comparison purposes.

The success of the PREVENT-Alzheimer program will stem from the much needed preliminary information generated about promising interventions in individuals who may have pre-symptomatic AD.

Prevention is the ultimate cure !

Download the poster or leaflet by clicking on the images below.

Prevent AD poster Prevent AD leaflet

Alzheimer's disease research links